Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Risdiplam

An RNA splicing modifier of the SMN2 gene for spinal muscular atrophy: it helps cells make more working SMN protein. Approved in the United States in August 2020. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It was the first oral treatment for spinal muscular atrophy: a liquid taken at home, which in 2022 was also approved for babies under 2 months of age.

RisdiplamGo to the active ingredient →
RisdiplamActive ingredientRisdiplamCat. No. P-R066-001CAS 1825352-65-5

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.